Free Trial

Cidara Therapeutics (CDTX) News Today

Cidara Therapeutics logo
$18.99 -0.71 (-3.62%)
Closing price 03:59 PM Eastern
Extended Trading
$18.96 -0.03 (-0.14%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CDTX Latest News

Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Shares Acquired by BVF Inc. IL
BVF Inc. IL increased its position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 55.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,092,796 shares of the bi
Cidara Therapeutics, Inc. stock logo
Alethea Capital Management LLC Sells 65,597 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Alethea Capital Management LLC lowered its stake in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 82.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,311 shares of the biotechn
Cidara Therapeutics, Inc. stock logo
54,473 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Bought by Acuta Capital Partners LLC
Acuta Capital Partners LLC purchased a new position in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 54,473 shares of the biotechnology company's
Cidara Therapeutics, Inc. stock logo
Boothbay Fund Management LLC Makes New Investment in Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Boothbay Fund Management LLC purchased a new stake in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,601 shares of the biotechnology company's stock, val
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by Brokerages
Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have been given a consensus recommendation of "Buy" by the nine research firms that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two have
Cidara Therapeutics, Inc. stock logo
RA Capital Management L.P. Purchases 389,716 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX)
RA Capital Management L.P. increased its position in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 55.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,092,796 shares of the biotechnology company's stock aft
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics (CDTX) to Release Earnings on Thursday
Cidara Therapeutics (NASDAQ:CDTX) will be releasing its Q1 2025 earnings after the market closes on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-cidara-therapeutics-inc-stock/)
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics (NASDAQ:CDTX) Given Market Outperform Rating at JMP Securities
JMP Securities reissued a "market outperform" rating and issued a $46.00 target price on shares of Cidara Therapeutics in a research note on Tuesday.
Cidara Therapeutics, Inc. stock logo
1,005,901 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Bought by TCG Crossover Management LLC
TCG Crossover Management LLC bought a new stake in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,005,901 shares of the biotechnology company's stock, valu
Cidara Therapeutics, Inc. stock logo
Adage Capital Partners GP L.L.C. Increases Stock Holdings in Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Adage Capital Partners GP L.L.C. increased its position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 765.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 369,954 shares of the biotechno
Cidara Therapeutics, Inc. stock logo
Vivo Capital LLC Purchases Shares of 670,600 Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Vivo Capital LLC purchased a new position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 670,600 shares of the biotechnology compan
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics (NASDAQ:CDTX) Upgraded to "Sell" at StockNews.com
StockNews.com raised shares of Cidara Therapeutics to a "sell" rating in a research report on Wednesday.
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics' (CDTX) "Buy" Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC restated a "buy" rating and issued a $35.00 target price on shares of Cidara Therapeutics in a research note on Thursday.
Cidara Therapeutics, Inc. stock logo
24,938 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Bought by ADAR1 Capital Management LLC
ADAR1 Capital Management LLC bought a new position in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 24,938 shares of the biotechnology co
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of "Buy" from Analysts
Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) has earned an average recommendation of "Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy ra
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics (NASDAQ:CDTX) Raised to Sell at StockNews.com
StockNews.com upgraded Cidara Therapeutics to a "sell" rating in a report on Friday.
Cidara Therapeutics, Inc. stock logo
Short Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Expands By 21.9%
Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 289,900 shares, an increase of 21.9% from the February 28th total of 237,800 shares. Based on an average daily trading volume, of 122,300 shares, the days-to-cover ratio is currently 2.4 days. Approximately 4.2% of the company's stock are sold short.
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics (NASDAQ:CDTX) Shares Pass Above 50 Day Moving Average - Time to Sell?
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Crosses Above Fifty Day Moving Average - Here's What Happened
Cidara Therapeutics to present on CD388 at ICAR 2025
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Growth in Short Interest
Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 237,800 shares, an increase of 30.7% from the February 13th total of 182,000 shares. Based on an average trading volume of 100,100 shares, the days-to-cover ratio is presently 2.4 days. Currently, 3.5% of the company's shares are sold short.
Cidara Therapeutics, Inc. stock logo
Shane Ward Sells 1,664 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) Stock
Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) COO Shane Ward sold 1,664 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $21.96, for a total transaction of $36,541.44. Following the sale, the chief operating officer now directly owns 14,674 shares of the company's stock, valued at $322,241.04. This represents a 10.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Leslie Tari Sells 1,773 Shares
Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) insider Leslie Tari sold 1,773 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $21.96, for a total transaction of $38,935.08. Following the completion of the transaction, the insider now directly owns 16,215 shares in the company, valued at $356,081.40. This represents a 9.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have received an average rating of "Buy" from the eight ratings firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the compan
Cidara Therapeutics initiated with an Outperform at Citizens JMP
Cidara Therapeutics, Inc. stock logo
Analysts Issue Forecasts for CDTX FY2029 Earnings
Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - HC Wainwright issued their FY2029 earnings estimates for shares of Cidara Therapeutics in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will po
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by Analysts at Citizens Jmp
Citizens Jmp initiated coverage on Cidara Therapeutics in a report on Wednesday. They issued an "outperform" rating and a $46.00 price target on the stock.
Cidara Therapeutics, Inc. stock logo
HC Wainwright Has Pessimistic Outlook of CDTX Q1 Earnings
Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - Analysts at HC Wainwright cut their Q1 2025 EPS estimates for Cidara Therapeutics in a research report issued on Monday, March 10th. HC Wainwright analyst E. Arce now anticipates that the biotechnology company will post earnings of ($5.45) p
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $35.00
HC Wainwright increased their target price on Cidara Therapeutics from $24.00 to $35.00 and gave the company a "buy" rating in a research note on Monday.
Cidara Therapeutics, Inc. stock logo
Cidara Therapeutics (NASDAQ:CDTX) Releases Earnings Results, Misses Estimates By $0.10 EPS
Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($5.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.28) by ($0.10). Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 69.64%.
Cidara Therapeutics reports Q4 EPS ($5.37) vs. (71c) last year
Get Cidara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

CDTX Media Mentions By Week

CDTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CDTX
News Sentiment

1.06

0.64

Average
Medical
News Sentiment

CDTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CDTX Articles
This Week

13

2

CDTX Articles
Average Week

Get Cidara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CDTX) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners